• Takeda Pharmaceutical (NYSE:TAK) has inked a collaboration agreement with privately held Alloy Therapeutics to develop the former's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).
• The companies noted that the paternship will help Alloy develop therapies to treat solid and hematological malignancies.
• A news release noted that iCAR-T "has potential to develop 'off-the-shelf' cell therapies, offering the potential for best-in-class performance with enhanced potency, and significantly lower manufacturing costs compared to autologous cell therapy."
• Terms call for Alloy to receive co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Also, the company wll use its exisiting expertise to advance the iCAR-T/NK platforms and provide broader access to the technology for future partners.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。